Lv1
35 积分 2022-02-11 加入
1496 JSKN033, an innovative subcutaneous-injected fixed-dose combination (FDC) of biparatopic anti-HER2 antibody drug conjugate (ADC) and PD-L1 inhibitor in advanced solid tumor
1个月前
已完结
1496 JSKN033, an innovative subcutaneous-injected fixed-dose combination (FDC) of biparatopic anti-HER2 antibody drug conjugate (ADC) and PD-L1 inhibitor in advanced solid tumor
1个月前
已完结
Subcutaneous Administration of Antibody-drug Conjugates
1个月前
已完结
High-dose subcutaneous Administration of Biologics: Overcoming barriers through formulation and device innovation
1个月前
已完结
Effects of annealing lyophilized and spray‐lyophilized formulations of recombinant human interferon‐γ
1个月前
已完结
A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations
2个月前
已完结
A Formulation Development Approach to Identify and Select Stable Ultra–High-Concentration Monoclonal Antibody Formulations With Reduced Viscosities
2个月前
已完结
Nanoantibodies: small molecules, big possibilities
2个月前
已关闭
Subcutaneous Administration of Antibody-drug Conjugates
2个月前
已完结
Subcutaneous Administration of Antibody-drug Conjugates
2个月前
已完结
皖公网安备34019202002308
